T. Roider

Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities

A single-cell multi-omic and spatial atlas of B cell lymphomas reveals differentiation drives intratumor heterogeneity

This study reveals that cellular differentiation drives intratumor heterogeneity in B-cell lymphomas, with distinct maturation states associated with different survival outcomes.

Proteomic profiling identifies Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in B-cell lymphoma

High-dimensional single-cell definition of CLL T cells identifies Galectin-9 as novel immunotherapy target

The paper defines CLL T cell subtypes and identifies Galectin-9 as a novel immunotherapy target through single-cell and multi-omics analyses.

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

The paper performs a proteogenomic analysis of chronic lymphocytic leukemia, identifies a new poor-prognosis subgroup (ASB-CLL) through proteomic profiling, and links it to clinical outcomes.

Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies

This study compares monoculture and stromal coculture for drug screening in hematological malignancies, finding that coculture reduces drug efficacy for many compounds but increases it for JAK inhibitors.

Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLL

This paper maps drug-microenvironment interactions in CLL to identify resistance mechanisms and patient subgroups, revealing how microenvironmental stimuli and genetic alterations influence drug response.

EOMES and IL-10 regulate anti-tumor activity of PD-1+ CD4+ T-cells in B-cell Non-Hodgkin lymphoma

Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level

This study examines intratumor heterogeneity in B cell lymphomas by analyzing transcriptional, genetic, and drug response profiles across malignant subclones and immune cells.